Business Context and Reporting Period
Company: ImmuCell Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2002
Business Overview: The Company operates in two primary segments: Animal Health Products and Research & Development (R&D). Its principal customers are in the U.S. dairy and beef industries. Key products include FIRST DEFENSE(R) and KAMAR(R) HEATMOUNT(R) DETECTOR. The Company is currently developing MAST OUT(TM), a non-antibiotic treatment for mastitis in dairy cows.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2002 | Six Months Ended June 30, 2002 |
|---|---|---|
| Total Revenues | $1,557,141 | $3,453,815 |
| Net Income (Loss) | $(22,624) | $146,431 |
| Net Income Per Share (Diluted) | $(0.01) | $0.05 |
| Operating Cash Flow | N/A (Six-month only) | $372,924 |
| Cash and Cash Equivalents | $1,299,280 | $1,299,280 |
| Short-term Investments | $489,145 | $489,145 |
| Total Debt | $0 | $0 |
| Working Capital | $2,942,867 | $2,942,867 |
Note: Gross margin on product sales was 40% for the three months ended June 30, 2002, and 46% for the six-month period.
Material Changes vs. Prior Period
- Revenue: Total revenues decreased 15% ($280,000) for the three months ended June 30, 2002, compared to the prior year, primarily due to a 21% decline in product sales. However, for the six-month period, total revenues increased 4% ($128,000) driven by a significant increase in grant income.
- Profitability: The Company reported a net loss of $22,624 for the quarter, compared to net income of $105,431 in the prior year quarter. For the six-month period, net income decreased 34% to $146,431 from $221,538.
- Debt Repayment: In May 2002, the Company utilized approximately $405,000 in cash to fully repay its outstanding bank mortgage. The Company currently has no outstanding bank debt.
- Inventory: Inventories increased by $230,206 during the six-month period, reflecting higher work-in-process and finished goods.
- Grant Income: Grant income increased significantly, rising $89,000 for the quarter and $149,000 for the six-month period compared to 2001, largely supporting the MAST OUT(TM) development.
Guidance, Outlook, and Risks
- Outlook: Management anticipates an increase in R&D expenses later in the year as the MAST OUT(TM) product advances to the clinical trial stage. The Company expects sales and marketing expenses to remain close to 20% of product sales as new products are launched.
- Liquidity: Management believes current capital resources are sufficient to meet working capital requirements and finance operations for at least the next twelve months.
- Risks and Contingencies:
- Regulatory Approval: MAST OUT(TM) is subject to U.S. Food and Drug Administration (FDA) approval.
- Seasonality: Sales of FIRST DEFENSE(R) are seasonal, with lower sales expected in late spring and summer.
- Deferred Revenue: $272,000 is recorded as deferred revenue, including $200,000 from a State of Maine grant with a contingent pay-back obligation if the product is not commercialized (though no pay-back is required if development is discontinued).
- Unusual Items: The Company recognized $30,000 in revenue from the sale of an option to technology (AgriCell Company, LLC) to be recognized over a 20-month period.
Investor Verification Checklist
- Verify the status and timeline of the FDA clinical trials for the MAST OUT(TM) product, as this drives future R&D costs and potential revenue.
- Confirm the terms of the $200,000 State of Maine grant, specifically the conditions under which the contingent pay-back obligation would be triggered.
- Monitor the seasonality of FIRST DEFENSE(R) sales and the impact of the backlog elimination in late 2001 on future quarterly comparisons.
- Review the progress of the option agreement with DMV International Nutritionals regarding the AgriCell Company, LLC joint venture.
- Assess the Company's ability to maintain gross margins as it shifts product mix toward new, lower-margin licensed products versus higher-margin proprietary products.